Thiazolidinediones and Weight Gain
Thiazolidinediones are tablets that make the body respond better to insulin but typically add two to five kilograms in the first year, mostly as fluid and subcutaneous fat rather than harmful visceral fat.
Plain English
Patient-Friendly Explanation
Thiazolidinediones, often called glitazones, are tablets used to treat type 2 diabetes. They work by making fat cells, muscle and liver more sensitive to insulin, so the body clears glucose more effectively. The most commonly used one today is pioglitazone; rosiglitazone, the other member of the class, was withdrawn or restricted in many countries after concerns about heart attacks. Weight gain is the side effect patients notice most, and it is real: most people add about two to five kilograms over the first year, a little more when the drug is combined with insulin or other diabetes tablets. It helps to know what that weight is made of. Part is fluid - the drug makes the kidneys hold on to sodium, so ankles can swell and blood volume rises - and part is new fat laid down under the skin, which is the metabolically safer place for fat to sit. At the same time, fat inside the abdomen and inside the liver usually falls, cholesterol and triglycerides often improve, and blood sugar control gets better, so the number on the scale is not the whole story. What does matter is watching for warning signs: swelling of the feet and ankles, several kilos of weight gain over days, or shortness of breath can signal fluid retention and heart failure, and glitazones carry a strong warning for people with heart failure. A portion-controlled diet and regular exercise can prevent most of the gain, and in trials intensive lifestyle support removed it entirely.
Medical
Clinical Definition
Thiazolidinediones are synthetic agonists of the peroxisome proliferator-activated receptor gamma, which is expressed most densely in white adipose tissue. Activation drives adipocyte differentiation and fatty-acid uptake through targets such as CD36 and FABP4, promotes GLUT4-mediated glucose uptake, and expands subcutaneous adipose capacity, sequestering circulating non-esterified fatty acids away from liver and skeletal muscle; circulating adiponectin rises two- to three-fold, which activates AMP-activated protein kinase and improves hepatic and muscle insulin sensitivity. The consequence is a characteristic body-composition change: total body weight and subcutaneous fat increase while visceral adipose tissue and intrahepatic lipid fall. Weight gain is dose-related, ranging from roughly 0.3 to 3.6 kg in monotherapy trials and 0.9 to 5.5 kg in combination with metformin, insulin or a sulphonylurea; a practical figure is 2-5 kg over 6-12 months, of which approximately 1-2 kg is fluid that plateaus by about week 12. In the PIVENS trial of pioglitazone 30 mg daily for 96 weeks in non-diabetic steatohepatitis, weight increased by a mean of 4.7 kg against 0.7 kg with placebo, while hepatic fat fell by about 50% and histological improvement occurred in 47% versus 22%; in PROactive, mean weight gain was 3.6 kg over 34.5 months with reductions in visceral and hepatic fat on imaging substudies. Adverse effects and monitoring: peripheral oedema in roughly 4-5%, plasma volume expansion, dose-dependent heart failure risk with a boxed warning for New York Heart Association class III or IV disease, weight gain, a roughly two-fold increase in fracture risk in women (best documented for rosiglitazone), rare macular oedema, and a contested bladder-cancer signal for pioglitazone. Rosiglitazone was withdrawn in Europe in 2010 and restricted in the United States after meta-analyses suggested increased myocardial infarction, leaving pioglitazone with a narrow niche, principally insulin resistance with biopsy-proven steatohepatitis and selected patients in whom other agents are unsuitable. Lifestyle intervention is an effective antidote: in randomised work, pioglitazone with a portion-controlled diet produced weight loss of 2.59 kg where the same drug with routine dietary advice produced a gain of 2.15 kg, and graded lifestyle programme intensity changed six-month weight from +4.9 kg to -0.2 kg.
Key Insight
Why It Matters
Gaining weight on a glitazone is expected, and much of it is fluid and subcutaneous fat while the fat inside the liver and abdomen usually falls - so the treatment may still be helping even as the scale climbs. Report ankle swelling, a rapid change in weight or breathlessness straight away, and pair the tablet with portion control rather than with hope.
Sources
Reviewed against standard medical references.
Medically reviewed by
Family Physician & Registered Acupuncturist, Accord Medical Clinic. MBBS (NUS), Graduate Diploma in Family Medicine (NUS), Graduate Diploma in Acupuncture (Singapore College of TCM).
Last reviewed: September 2026
This page is general health education, not medical advice. Whether any treatment is appropriate for you is a decision made in consultation after assessment.
